PDRN for Eczema-Prone Skin: What the Science Suggests

One person in a skincare community described years of flaky skin and eczema spots that cleared after three monthly PDRN injection sessions. Another mentioned their eczema-prone skin responded well to a PDRN jelly cream, finding it hydrating without irritation. These individual accounts are not clinical evidence — but they point toward a plausible biological connection worth examining honestly.

Eczema (atopic dermatitis) is a chronic inflammatory skin condition characterised by a compromised skin barrier, immune dysregulation, and persistent inflammation. PDRN has documented mechanisms that address at least two of those three factors directly. Whether that translates to meaningful benefit for eczema-prone skin in practice — and in what form — is a more complicated question.

The Filaggrin Connection

Filaggrin is one of the most important proteins in the skin barrier. It forms the structural backbone of the stratum corneum — the outermost layer of skin — and plays a critical role in maintaining the barrier's integrity and water-retention capacity. Loss-of-function mutations in the filaggrin gene (FLG) are the strongest known genetic risk factor for atopic dermatitis. People with eczema almost universally have reduced filaggrin expression, whether through genetics or chronic inflammation.

PDRN upregulates filaggrin. A 2023 study (Kim et al., PMC10649580) confirmed this in both cell cultures and an artificial skin model, finding that PDRN significantly increased filaggrin expression alongside other key barrier proteins including fibronectin and Ki-67. This is not a peripheral finding — it goes directly to the core structural deficit of eczema-prone skin.

The Anti-Inflammatory Mechanism

Eczema flares are driven by Th2-dominant immune activation, triggering cytokines including IL-4, IL-13, and IL-31. The resulting inflammation degrades the barrier further, creating a cycle that is difficult to break. PDRN's A2A receptor activation suppresses NF-kB and MAPK — two central inflammatory signalling pathways. Multiple systematic reviews have found PDRN reduced inflammation in every experimental model where it was tested.

The specific cytokine profile of eczema (Th2-driven) is different from the inflammatory profile PDRN has been most extensively tested against (wound healing and general skin inflammation). Whether PDRN's anti-inflammatory action meaningfully interrupts the eczema-specific cytokine cascade is not yet confirmed in published clinical trials. The mechanism is plausible — but plausible is not the same as proven.

What the Evidence Does and Does Not Support

There are no published randomised controlled trials of PDRN specifically for atopic dermatitis. The existing evidence is a combination of mechanistic data (filaggrin upregulation, anti-inflammatory receptor activation) and community-reported experience. That is a meaningful signal but not a clinical conclusion.

What the evidence does support: PDRN has barrier-repair and anti-inflammatory properties that are mechanistically relevant to eczema. What it does not support: that PDRN is a treatment for eczema, that it replaces established treatments, or that results documented in non-eczema populations can be assumed to apply to eczema-prone skin.

Eczema is a medical condition. If you have atopic dermatitis, your treatment plan should be led by a dermatologist — not by skincare community discussion or ingredient research, including this article. Any changes to your routine, including adding new active ingredients, are worth discussing with your doctor first.